New requirements for phase I trials: a challenge for Italian clinical research.

Emanuela Marchesi, Manuela Monti, Oriana Nanni, L. Bassi, Martina Piccinni Leopardi, Celeste Cagnazzo

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

BACKGROUND:
In 2015, the Italian Medicines Agency (Agenzia Italiana del Farmaco; AIFA) issued the Determination 809/2015 with new requirements for phase I clinical trials. Before it came into force, we explored the extent to which several Italian oncology centers were working to implement it.
METHODS:
A survey was conducted among 80 Italian centers involved in clinical trials. Investigators and research coordinators were surveyed.
RESULTS:
Answers from 42 institutions were collected: among them 88.1% were involved in oncology research. In the last 5 years, 55% had conducted from 1 to 5 phase I trials, and only 16.7% more than 5. A third were involved in not-first-in-human research and none with healthy volunteers. The majority (57.1%) of the centers did not run any projects and trials are non-commercial, and about 35%, no more than 2. While 9.5% already met the standards for self-certification, 71.4% were working to achieve them. Standard operating procedures dedicated to research and the required good clinical practice training had been established by 57.1% and 76.2%, respectively. Fifty percent of laboratories were almost compliant with the Determination. After 10 months from its coming into force, 98 sites had applied for certification, of which 34 were oncology units.
CONCLUSIONS:
The new AIFA Determination imposes a certified organizational model on units and laboratories involved in phase I trials. Our results showed that great efforts were made to qualify for phase I research suggesting that other oncology units will apply for certification in the near future. Predictably, Italy will set the pace as a highly qualified country in which to conduct early-phase research.
Original languageEnglish
JournalTumori
DOIs
Publication statusPublished - 2017

Fingerprint

Certification
Research
Organizational Models
Clinical Trials, Phase I
Italy
Healthy Volunteers
Research Personnel
Clinical Trials

Cite this

New requirements for phase I trials: a challenge for Italian clinical research. / Marchesi, Emanuela; Monti, Manuela; Nanni, Oriana; Bassi, L.; Piccinni Leopardi, Martina; Cagnazzo, Celeste.

In: Tumori, 2017.

Research output: Contribution to journalArticle

@article{c8d1bdabee6c4faab024f891d3e345a3,
title = "New requirements for phase I trials: a challenge for Italian clinical research.",
abstract = "BACKGROUND:In 2015, the Italian Medicines Agency (Agenzia Italiana del Farmaco; AIFA) issued the Determination 809/2015 with new requirements for phase I clinical trials. Before it came into force, we explored the extent to which several Italian oncology centers were working to implement it.METHODS:A survey was conducted among 80 Italian centers involved in clinical trials. Investigators and research coordinators were surveyed.RESULTS:Answers from 42 institutions were collected: among them 88.1{\%} were involved in oncology research. In the last 5 years, 55{\%} had conducted from 1 to 5 phase I trials, and only 16.7{\%} more than 5. A third were involved in not-first-in-human research and none with healthy volunteers. The majority (57.1{\%}) of the centers did not run any projects and trials are non-commercial, and about 35{\%}, no more than 2. While 9.5{\%} already met the standards for self-certification, 71.4{\%} were working to achieve them. Standard operating procedures dedicated to research and the required good clinical practice training had been established by 57.1{\%} and 76.2{\%}, respectively. Fifty percent of laboratories were almost compliant with the Determination. After 10 months from its coming into force, 98 sites had applied for certification, of which 34 were oncology units.CONCLUSIONS:The new AIFA Determination imposes a certified organizational model on units and laboratories involved in phase I trials. Our results showed that great efforts were made to qualify for phase I research suggesting that other oncology units will apply for certification in the near future. Predictably, Italy will set the pace as a highly qualified country in which to conduct early-phase research.",
author = "Emanuela Marchesi and Manuela Monti and Oriana Nanni and L. Bassi and {Piccinni Leopardi}, Martina and Celeste Cagnazzo",
year = "2017",
doi = "10.5301/tj.5000668",
language = "English",
journal = "Tumori",
issn = "0300-8916",
publisher = "SAGE Publications Ltd",

}

TY - JOUR

T1 - New requirements for phase I trials: a challenge for Italian clinical research.

AU - Marchesi, Emanuela

AU - Monti, Manuela

AU - Nanni, Oriana

AU - Bassi, L.

AU - Piccinni Leopardi, Martina

AU - Cagnazzo, Celeste

PY - 2017

Y1 - 2017

N2 - BACKGROUND:In 2015, the Italian Medicines Agency (Agenzia Italiana del Farmaco; AIFA) issued the Determination 809/2015 with new requirements for phase I clinical trials. Before it came into force, we explored the extent to which several Italian oncology centers were working to implement it.METHODS:A survey was conducted among 80 Italian centers involved in clinical trials. Investigators and research coordinators were surveyed.RESULTS:Answers from 42 institutions were collected: among them 88.1% were involved in oncology research. In the last 5 years, 55% had conducted from 1 to 5 phase I trials, and only 16.7% more than 5. A third were involved in not-first-in-human research and none with healthy volunteers. The majority (57.1%) of the centers did not run any projects and trials are non-commercial, and about 35%, no more than 2. While 9.5% already met the standards for self-certification, 71.4% were working to achieve them. Standard operating procedures dedicated to research and the required good clinical practice training had been established by 57.1% and 76.2%, respectively. Fifty percent of laboratories were almost compliant with the Determination. After 10 months from its coming into force, 98 sites had applied for certification, of which 34 were oncology units.CONCLUSIONS:The new AIFA Determination imposes a certified organizational model on units and laboratories involved in phase I trials. Our results showed that great efforts were made to qualify for phase I research suggesting that other oncology units will apply for certification in the near future. Predictably, Italy will set the pace as a highly qualified country in which to conduct early-phase research.

AB - BACKGROUND:In 2015, the Italian Medicines Agency (Agenzia Italiana del Farmaco; AIFA) issued the Determination 809/2015 with new requirements for phase I clinical trials. Before it came into force, we explored the extent to which several Italian oncology centers were working to implement it.METHODS:A survey was conducted among 80 Italian centers involved in clinical trials. Investigators and research coordinators were surveyed.RESULTS:Answers from 42 institutions were collected: among them 88.1% were involved in oncology research. In the last 5 years, 55% had conducted from 1 to 5 phase I trials, and only 16.7% more than 5. A third were involved in not-first-in-human research and none with healthy volunteers. The majority (57.1%) of the centers did not run any projects and trials are non-commercial, and about 35%, no more than 2. While 9.5% already met the standards for self-certification, 71.4% were working to achieve them. Standard operating procedures dedicated to research and the required good clinical practice training had been established by 57.1% and 76.2%, respectively. Fifty percent of laboratories were almost compliant with the Determination. After 10 months from its coming into force, 98 sites had applied for certification, of which 34 were oncology units.CONCLUSIONS:The new AIFA Determination imposes a certified organizational model on units and laboratories involved in phase I trials. Our results showed that great efforts were made to qualify for phase I research suggesting that other oncology units will apply for certification in the near future. Predictably, Italy will set the pace as a highly qualified country in which to conduct early-phase research.

U2 - 10.5301/tj.5000668

DO - 10.5301/tj.5000668

M3 - Article

JO - Tumori

JF - Tumori

SN - 0300-8916

ER -